Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

被引：0
|
作者：
Bachir, B. [1 ]
Anouti, S. [1 ]
Jaoude, J. Abi [1 ]
Kayali, M. [1 ]
Tfayli, A. [1 ]
De Azambuja, E. [2 ]
Poortmans, P. [3 ]
Zeidan, Y. [1 ,4 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Beirut, Lebanon
[2] ULB, Brussels, Belgium
[3] Iridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium
[4] Baptist Hlth South Florida, Lynn Canc Inst, Boca Raton, FL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] RETROSPECTIVE ANALYSIS OF CARDIAC MEDICATIONS IN THE PREVENTION OF CARDIOTOXICITY IN TRASTUZUMAB-TREATED HER2 POSITIVE BREAST CANCER PATIENTS
    Moey, Melissa
    Liles, Darla K.
    Carabello, Blase
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 694 - 694
  • [32] Trastuzumab and oral vinorelbine (±endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer.
    Torrisi, R.
    Magni, E.
    Dellapasqua, S.
    D'Alessandro, C.
    Veronesi, P.
    Luini, A.
    Minchella, I
    Ghisini, R.
    Nole, F.
    Viale, G.
    Goldhirsch, A.
    Colleoni, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [33] Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
    Masafumi Kurosumi
    Breast Cancer, 2009, 16 : 284 - 287
  • [34] Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
    Kurosumi, Masafumi
    BREAST CANCER, 2009, 16 (04) : 284 - 287
  • [35] The Impact of Trastuzumab on the Pulmonary Artery Systolic Pressure in Patients With HER-2 Positive Breast Cancer
    Abdulelah, Zaid A.
    Khrais, Mohammad Z.
    Ghalayni, Ruba A.
    Al-Khalili, Faris
    Alqaisieh, Mohammad
    AbuAlSha'r, Mu'taz F.
    Abdulelah, Ahmed A.
    Abandeh, Yazan S.
    Al-Rimawi, Dalia
    Hamam, Ismail R.
    CIRCULATION, 2022, 146
  • [36] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Anna Cardillo
    Raffaella Ghisini
    Andrea Rocca
    Alessandra Balduzzi
    Rosalba Torrisi
    Giulia Peruzzotti
    Aron Goldhirsch
    Elisabetta Pietri
    Marco Colleoni
    BMC Cancer, 6
  • [37] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Orlando, Laura
    Cardillo, Anna
    Ghisini, Raffaella
    Rocca, Andrea
    Balduzzi, Alessandra
    Torrisi, Rosalba
    Peruzzotti, Giulia
    Goldhirsch, Aron
    Pietri, Elisabetta
    Colleoni, Marco
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 76
  • [38] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Orlando, Laura
    Cardillo, Anna
    Ghisini, Raffaella
    Rocca, Andrea
    Balduzzi, Alessandra
    Torrisi, Rosalba
    Peruzzotti, Giulia
    Goldhirsch, Aron
    Pietri, Elisabetta
    Colleoni, Marco
    BMC CANCER, 2006, 6 (1)
  • [39] Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
    Pascual-Mathey, Luz I.
    Velez-Figueroa, Midory I.
    Diaz-Vallejo, Joel J.
    Mendez-Hirata, Gustavo
    Mendez-Machado, Gustavo F.
    REPORTS, 2024, 7 (03)
  • [40] Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.
    Schiavone, Andrea
    Diaz, Mariana
    Camejo, Natalia
    Reborido, Natalia
    Vazquez, Horacio
    Parma, Gabriel
    Vazquez, Alvaro
    Castillo, Cecilia
    Krygier, Gabriel David
    Delgado, Lucia Beatriz
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
12345